Market News

Northern Cross Has Upped Teva Pharmaceutical (TEVA) Position by $84.47 Million as Valuation Declined; As Henry Schein (HSIC) Market Valuation Rose, Bbva Compass Bancshares Raised Holding by $985,804

Bbva Compass Bancshares Inc increased its stake in Henry Schein Inc (HSIC) by 86.69% based on its latest 2017Q3 regulatory filing with the SEC. Bbva Compass Bancshares Inc bought 12,022 shares as the company’s stock rose 5.77% with the market. The institutional investor held 25,890 shares of the health care company at the end of 2017Q3, valued at $2.12M, up from 13,868 at the end of the previous reported quarter. Bbva Compass Bancshares Inc who had been investing in Henry Schein Inc for a number of months, seems to be bullish on the $10.88 billion market cap company. The stock increased 1.99% or $1.35 during the last trading session, reaching $69.32. About 928,084 shares traded. Henry Schein, Inc. (NASDAQ:HSIC) has risen 4.05% since February 21, 2017 and is uptrending. It has underperformed by 12.65% the S&P500.

Northern Cross Llc increased its stake in Teva Pharmaceutical (TEVA) by 27.92% based on its latest 2017Q3 regulatory filing with the SEC. Northern Cross Llc bought 4.97 million shares as the company’s stock declined 15.11% while stock markets rallied. The institutional investor held 22.76 million shares of the major pharmaceuticals company at the end of 2017Q3, valued at $400.65M, up from 17.80M at the end of the previous reported quarter. Northern Cross Llc who had been investing in Teva Pharmaceutical for a number of months, seems to be bullish on the $20.50B market cap company. The stock increased 0.89% or $0.1778 during the last trading session, reaching $20.1578. About 4.94 million shares traded. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has declined 41.70% since February 21, 2017 and is downtrending. It has underperformed by 58.40% the S&P500.

Since September 6, 2017, it had 0 buys, and 1 sale for $366,756 activity.

Bbva Compass Bancshares Inc, which manages about $1.53 billion US Long portfolio, decreased its stake in Visa Inc. (NYSE:V) by 7,105 shares to 160,550 shares, valued at $16.90M in 2017Q3, according to the filing. It also reduced its holding in Ishares Core S&P 500 Etf (IVV) by 1,596 shares in the quarter, leaving it with 65,791 shares, and cut its stake in Tjx Companies Inc (NYSE:TJX).

Investors sentiment increased to 7.15 in 2017 Q3. Its up 5.99, from 1.16 in 2017Q2. It improved, as 47 investors sold HSIC shares while 15 reduced holdings. 66 funds opened positions while 377 raised stakes. 279.70 million shares or 306.41% more from 68.82 million shares in 2017Q2 were reported. Amalgamated Bank & Trust accumulated 0.05% or 19,052 shares. Thrivent Fincl For Lutherans reported 0% of its portfolio in Henry Schein, Inc. (NASDAQ:HSIC). Kentucky Retirement System owns 0.06% invested in Henry Schein, Inc. (NASDAQ:HSIC) for 9,742 shares. 10,850 are held by Lpl Finance Ltd Llc. Ftb Advisors Inc holds 0.01% of its portfolio in Henry Schein, Inc. (NASDAQ:HSIC) for 1,484 shares. Advsrs Asset Management Inc holds 0.03% or 22,183 shares. Palisade Limited Nj invested in 17,880 shares or 0.05% of the stock. Pnc Fin Service Grp Inc has 0.01% invested in Henry Schein, Inc. (NASDAQ:HSIC) for 92,702 shares. Girard Prtn Limited reported 6,640 shares. Fdx Advsr Incorporated holds 10,200 shares or 0.02% of its portfolio. Cibc Corp owns 36,155 shares. Hutchin Hill Cap Lp reported 3,700 shares. 260,250 are owned by New York State Teachers Retirement. Gulf Interest Bankshares (Uk) Ltd has 49,870 shares. Numeric Investors Llc reported 0% stake.

Among 21 analysts covering Henry Schein Inc. (NASDAQ:HSIC), 11 have Buy rating, 1 Sell and 9 Hold. Therefore 52% are positive. Henry Schein Inc. had 45 analyst reports since July 31, 2015 according to SRatingsIntel. The company was maintained on Wednesday, September 27 by Jefferies. The stock of Henry Schein, Inc. (NASDAQ:HSIC) earned “Hold” rating by Stifel Nicolaus on Tuesday, November 7. The firm has “Outperform” rating by RBC Capital Markets given on Thursday, November 5. The company was upgraded on Tuesday, November 7 by Craig Hallum. As per Monday, September 12, the company rating was initiated by Bank of America. Robert W. Baird upgraded the shares of HSIC in report on Tuesday, January 3 to “Outperform” rating. Jefferies maintained the shares of HSIC in report on Tuesday, August 22 with “Hold” rating. Barrington Research maintained the shares of HSIC in report on Wednesday, February 22 with “Outperform” rating. The rating was maintained by Stifel Nicolaus on Tuesday, October 17 with “Hold”. PiperJaffray upgraded Henry Schein, Inc. (NASDAQ:HSIC) on Friday, September 15 to “Overweight” rating.

Northern Cross Llc, which manages about $51.96 billion and $7.77B US Long portfolio, decreased its stake in Series C by 179,447 shares to 5.64M shares, valued at $184.57M in 2017Q3, according to the filing. It also reduced its holding in Wynn Resorts Ltd (NASDAQ:WYNN) by 633,449 shares in the quarter, leaving it with 7.65M shares, and cut its stake in Alibaba Group Holding (NYSE:BABA).

Among 35 analysts covering Teva Pharma (NYSE:TEVA), 9 have Buy rating, 8 Sell and 18 Hold. Therefore 26% are positive. Teva Pharma had 146 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has “Outperform” rating given on Wednesday, November 16 by RBC Capital Markets. The stock has “Hold” rating by HSBC on Friday, November 4. The company was downgraded on Monday, October 24 by Mizuho. Credit Suisse downgraded the shares of TEVA in report on Thursday, August 24 to “Underperform” rating. RBC Capital Markets maintained Teva Pharmaceutical Industries Limited (NYSE:TEVA) rating on Wednesday, July 29. RBC Capital Markets has “Outperform” rating and $85 target. Goldman Sachs downgraded the shares of TEVA in report on Friday, July 15 to “Neutral” rating. The stock has “Outperform” rating by Leerink Swann on Tuesday, July 21. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) earned “Buy” rating by BTIG Research on Monday, September 11. On Wednesday, October 4 the stock rating was maintained by Barclays Capital with “Equal-Weight”. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has “Sell” rating given on Friday, January 26 by Leerink Swann.

Leave a Reply

Your email address will not be published. Required fields are marked *